Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) have been assigned a consensus rating of “Buy” from the five analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a strong buy rating on the company.

IKT has been the subject of a number of research reports. Cantor Fitzgerald raised Inhibikase Therapeutics to a “strong-buy” rating in a research report on Thursday, December 11th. Lifesci Capital raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Monday, December 1st. HC Wainwright upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a report on Friday, December 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Inhibikase Therapeutics to a “sell” rating in a research report on Saturday, December 27th.

Inhibikase Therapeutics Stock Down 1.2%

Shares of IKT stock opened at $1.65 on Wednesday. The firm has a market capitalization of $124.05 million, a price-to-earnings ratio of -4.23 and a beta of 0.84. Inhibikase Therapeutics has a one year low of $1.33 and a one year high of $3.32. The stock’s 50 day moving average is $1.65.

Inhibikase Therapeutics (NASDAQ:IKT) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.